Your browser doesn't support javascript.
loading
Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study.
Zaafar, Dalia; Khalil, Heba M A; Elkhouly, Gehad E; Sedeky, Abanoub Selim; Ahmed, Yasmine H; Khalil, Mona G; Abo-Zeid, Yasmin.
Afiliación
  • Zaafar D; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt. dalia.zaffar@pharm.mti.edu.eg.
  • Khalil HMA; Department of Veterinary Hygiene and Management, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt.
  • Elkhouly GE; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Helwan University, Cairo, 11795, Egypt.
  • Sedeky AS; Helwan Nanotechnology Center, Helwan University, Cairo, 11792, Egypt.
  • Ahmed YH; Department of Microsystems Engineering (IMTEK), University of Freiburg, Freiburg im Breisgau, Germany.
  • Khalil MG; Nanomedicine Lab, Center of Materials Science (CMS), Zewail City of Science and Technology, 6Th of October, 12578, Giza, Egypt.
  • Abo-Zeid Y; Department of Cytology and Histology, Veterinary Medicine Faculty, Cairo University, Giza, 12211, Egypt.
Article en En | MEDLINE | ID: mdl-38430357
ABSTRACT
Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer-related deaths worldwide. Current treatment strategies include surgical resection, liver transplantation, liver-directed therapy, and systemic therapy. Sorafenib (Sor) is the first systemic drug authorized by the US Food and Drug Administration (FDA) for HCC treatment. Nevertheless, the conventional oral administration of Sor presents several

limitations:

poor solubility, low bioavailability, drug resistance development, and off-target tissue accumulation, leading to numerous adverse effects. Nano-emulsion, a nano-delivery system, is a viable carrier for poorly water-soluble drugs. It aims to enhance drug bioavailability, target organ accumulation, and reduce off-target tissue exposure, thus improving therapeutic outcomes while minimizing side effects. This study formulated Sor nano-emulsion (Sor NanoEm) using the homogenization technique. The resultant nano-emulsion was characterized by particle size (121.75 ± 12 nm), polydispersity index (PDI; 0.310), zeta potential (-12.33 ± 1.34 mV), viscosity (34,776 ± 3276 CPs), and pH (4.38 ± 0.3). Transmission Electron Microscopy exhibited spherical nano-droplets with no aggregation signs indicating stability. Furthermore, the encapsulation of Sor within the nano-emulsion sustained its release, potentially reducing the frequency of therapeutic doses. Cytotoxicity assessments on the HepG2 cell line revealed that Sor NanoEm had a significantly (P < 0.05) more potent cytotoxic effect compared to Sor suspension. Subsequent tests highlighted superior pharmacokinetic parameters and reduced dosage requirements of Sor NanoEm in mice. It exhibited an enhanced safety profile, particularly in behavior, brain, and liver, compared to its suspended form. These findings underscore the enhanced pharmacological and toxicological attributes of Sor Nano-emulsion, suggesting its potential utility in HCC treatment.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Drug Deliv Transl Res Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Drug Deliv Transl Res Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Estados Unidos